3. GOOD HEALTH AND WELL-BEING

Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference – Business Wire

Written by Amanda
  1. Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference  Business Wire
  2. Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference  Yahoo Finance
  3. Zoetis to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference  The Bakersfield Californian
  4. AMGEN ANNOUNCES WEBCAST OF GOLDMAN SACHS 43RD ANNUAL HEALTHCARE CONFERENCE  Investing News Network
  5. View Full Coverage on Google News

BILLERICA, Mass.–()–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chief Executive Officer, Masoud Toloue, will join the Goldman Sachs 43rd Annual Global Healthcare Conference for a fireside chat on June 16, 2022 at 8:40 a.m., EST.

To register for the live webcast, please visit: https://kvgo.com/gs/quanterix-corp-june-2022.

Toloue will also host one-on-one meetings with institutional investors on Thursday, June 16. A live webcast of the conversation will be available on the investor section of the Quanterix website at https://ir.quanterix.com/investor-relations. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Source: businesswire.com

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment